BioRestorative Therapies (BRTX) shares were up past 5% in recent Monday premarket activity after the company said the Japanese Patent Office issued a notice of allowance for its ThermoStem platform.
The patent covers the company's allogeneic, off-the-shelf brown adipose-derived stem cell technology, intended to treat obesity and metabolic disorders, it said.
The company said that the patent encompasses therapeutic cells, as well as multiple methods of encapsulation and delivery, including alginate microcapsules, cellulose hydrogels, polymer membranes and advanced scaffolding systems.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments